EVI1 (MECOM) Breakapart
Chromosome rearrangements involving band 3q26.2 are associated with myeloid malignancies, aberrant expression of the human ecotropic virus integration site 1 (EVI1) gene, an unfavourable prognosis and an aggressive clinical course1.
The EVI1 gene encodes a 1051 amino acid zinc finger protein that is inappropriately expressed in the leukaemic cells of between 2-5% of AML and MDS patients2. EVI1 activation often follows a chromosomal rearrangement involving 3q26.2 and the two most common aberrations are the t(3;3)(q21;q26.2) and inv(3)(q21q26.2). EVI1 also exists as a longer protein, named MDS1/EVI1, created by splicing of the MDS1 and EVI1 mRNAs. This includes 188 additional amino acid residues at the N-terminus2. The breakpoints for the translocations and inversions vary considerably. Inv(3) breakpoints are found centromeric to, and including, the EVI1 gene and cover about 600kb. The majority of breakpoints in 3q26.2 translocations are telomeric to the EVI1 gene and cover a region including the telomeric end of the MDS1 gene and the MYNN gene1.
1. Bobadilla D et al., Br J Haematol 2007;136:806-13
2. Soderholm J et al., Leukemia 1997;11:352-8
- Area of Interest*
- AML, MDS
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.